TP53 and cancer: DDR deficiency results from mutations of large-scale upstream cancer suppressor genes, such as TP53, which is commonly mutated across pan-cancer and in at least 80% of LUSC cases, and is enhanced by the following clonal evolution of cells (Mandal et al., 2019).